Similarly, the interactions with human Myosin 9b RHOGAP, allosteric EYA2 phosphatase inhibitor, RSK4 N-terminal kinase, and human Collapsin Response Mediator Protein-1 showcased favourable scores and a range of interactions that suggest the potential of 3-1-BenCarMethInYlPro-Phosphonic acid as a multitargeted inhibitor of lung cancer-related proteins, warranting further experimental validation. This evidence concerns the gene EYA2 and lung carcinoma.